Gelderblom, H., Wang, V., Doherty, M., Sebio, A., Stacchiotti, S., Wilky, B. A., Blay, J., Brohl, A. S., Morales, C. M. V., Reichardt, P., Martin-Broto, J., Davis, E. J., Haan, J. J. D., O'Neill, B., Babcock, E., Garcia, J., Senne, L., Shepard, D., Chawla, S. P., Jones, R. L. (2026). The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.11504